What are the clinical efficacy, adverse effects, and recommended role of baxfendy (baxdrostat) in managing resistant hypertension?

Baxfendy (Baxdrostat) in Clinical Practice

Baxfendy is a highly effective add-on agent for resistant hypertension that reduces systolic blood pressure by approximately 14-17 mmHg when added to existing multidrug regimens, but requires vigilant potassium monitoring due to predictable hyperkalemia risk.

Clinical Efficacy

Baxfendy demonstrates robust blood pressure-lowering effects across multiple validated endpoints 1:

• Office Blood Pressure: Reduces seated systolic BP by 8-9 mmHg and diastolic BP by 3-4 mmHg compared to placebo at 12 weeks
• Ambulatory Monitoring: Produces a 14 mmHg reduction in 24-hour ambulatory systolic BP (the most clinically relevant measure) 2
• Dose Response: The 2 mg dose consistently outperforms 1 mg, with the 2 mg dose showing the most reliable efficacy across analytical approaches 3
• Patient Population: Tested in patients on ≥2 antihypertensive medications (including a diuretic), with baseline systolic BP 140-170 mmHg and eGFR ≥45 mL/min/1.73 m² 1

The mechanism—selective aldosterone synthase inhibition—directly addresses a key pathophysiologic driver in resistant hypertension without affecting cortisol production, distinguishing it from mineralocorticoid receptor antagonists 4.

Adverse Effects Profile

Primary Safety Concern - Hyperkalemia:

• Hyperkalemia (K+ ≥5.5 mmol/L) occurs 3-8 times more frequently than placebo 5, 6
• Severe hyperkalemia (>6.5 mmol/L) does not increase significantly, indicating most elevations are mild-to-moderate 5
• Only 3% of patients experienced confirmed potassium >6 mmol/L in pivotal trials 1
• Mean serum potassium increase: approximately 0.4-0.5 mmol/L 7

Other Adverse Effects:

• Overall adverse events occur more frequently (24% increase in relative risk) 8
• Critically: Serious adverse events, hypotension, hyponatremia, mortality, and discontinuation rates are comparable to placebo 5
• Modest eGFR reduction of ~5 mL/min/1.73 m² observed 7
• Unlike spironolactone, baxdrostat avoids gynecomastia, erectile dysfunction, and menstrual irregularities due to its selective mechanism 1

Role in Clinical Practice

Positioning in Treatment Algorithm

Baxfendy should be positioned as a fourth-line agent for resistant hypertension, after optimizing the foundational three-drug regimen but before resorting to less-tolerated options like minoxidil.

Based on integration of current guidelines 9, 4 with baxdrostat's evidence base:

Step 1-3 (Standard Foundation):

• Diuretic (thiazide or thiazide-like; loop if eGFR <30)
• ACE inhibitor or ARB (preferably azilsartan for superior BP reduction 9)
• Long-acting dihydropyridine calcium channel blocker (amlodipine or extended-release nifedipine)

Step 4 (Add Baxfendy):

• Indication: BP remains ≥140/90 mmHg despite maximally tolerated doses of the above three agents
• Dose: Start 2 mg once daily (use 1 mg only in patients at high hyperkalemia risk) 1
• Contraindications to starting: Baseline K+ >5.0 mmol/L, eGFR <45 mL/min/1.73 m² 1

Step 5 (If Baxfendy Insufficient):

• Add mineralocorticoid receptor antagonist (spironolactone 25-100 mg) if not already used—note that MRAs were excluded from baxdrostat trials 1
• Consider β-blocker or α-2 agonist if heart rate >80 bpm 9

Step 6-7 (Refractory Cases):

• Hydralazine (with β-blocker and diuretic background)
• Minoxidil as last resort 9

Practical Monitoring Protocol

Before Initiation:

• Verify eGFR ≥45 mL/min/1.73 m²
• Confirm serum potassium 3.5-5.0 mmol/L
• Ensure patient is not on both ACE inhibitor AND ARB simultaneously
• Discontinue any MRA or potassium-sparing diuretic 1

During Treatment:

• Check serum potassium at weeks 1,2,4,8, and 12, then quarterly 1
• Check serum sodium at same intervals (hyponatremia risk) 1
• Monitor eGFR quarterly
• More frequent monitoring if: age >65, diabetes, baseline eGFR 45-60, concomitant NSAIDs, or potassium 4.5-5.0 at baseline

Management of Hyperkalemia:

• K+ 5.5-6.0 mmol/L: Increase monitoring frequency, consider dietary counseling, continue drug
• K+ 6.0-6.5 mmol/L: Consider dose reduction to 1 mg or add potassium binder
• K+ >6.5 mmol/L: Hold drug, treat hyperkalemia, reassess risk-benefit

Key Clinical Advantages Over Alternatives

1. Versus Spironolactone: No hormonal side effects (gynecomastia, sexual dysfunction, menstrual changes); once-daily dosing 4, 1
2. Versus Eplerenone: More potent BP reduction; true once-daily pharmacokinetics (eplerenone requires twice-daily dosing) 9
3. Versus Hydralazine/Minoxidil: Better tolerability profile; no hirsutism, lupus-like syndrome, or severe fluid retention 9

Critical Caveats

• Not studied with concomitant MRAs: The combination may produce additive hyperkalemia risk—avoid simultaneous use 1
• Drug interactions: Strong/moderate CYP3A inducers may reduce efficacy; monitor BP more frequently if co-administered 1
• No long-term cardiovascular outcome data yet: Current evidence limited to 12-32 weeks; mortality/morbidity benefits extrapolated from BP reduction 1, 2
• Cost considerations: As a novel agent, likely more expensive than generic alternatives; reserve for true resistant hypertension after generic options optimized

When NOT to Use Baxfendy

• Baseline potassium >5.0 mmol/L
• eGFR <45 mL/min/1.73 m²
• Concurrent MRA or potassium-sparing diuretic use
• Patients unable to comply with frequent laboratory monitoring
• Uncontrolled hypertension due to non-adherence (address adherence first)
• Secondary hypertension not yet ruled out (screen for primary aldosteronism, renovascular disease, etc. before adding fourth agent) 4

The 2024 ESC Guidelines specifically mention baxdrostat as an emerging option being tested for primary aldosteronism and resistant hypertension 4, signaling its anticipated integration into standard treatment algorithms as evidence matures.